BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pyrotinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pyrotinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06015048-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT06015048)
DESCRIPTION:Pyrotinib\, phase 1/2.\nStudy: A Trial of SHR-A1811 Combined Wi
 th Other Antitumor Therapies in Advanced Solid Tumors.\nEstimated primary 
 completion: November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06015048
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06035679-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pyrotinib: Phase na readout est. (NCT06035679)
DESCRIPTION:Pyrotinib\, phase na\, HER2-Positive Breast Cancer.\nStudy: Pyr
 otinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for 
 HER2-positive Breast Cancer\nEstimated primary completion: 30 November 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06035679
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Pyrotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A T
 rial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in 
 Subjects With Advanced Non-small Cell Lung Cancer\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05482568
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04486911-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT04486911)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Pyrotinib Maleate\, CDK4/6 Inhibit
 or and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial\nE
 stimated primary completion: 1 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04486911
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04290793-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pyrotinib: Phase 2/3 readout est. (NCT04290793)
DESCRIPTION:Pyrotinib\, phase 2/3.\nStudy: Neoadjuvant Chemotherapy With Py
 rotinib\, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzu
 mab for HER-2+ Breast Cancer\nEstimated primary completion: 1 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04290793
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05751018-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT05751018)
DESCRIPTION:Pyrotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase
  II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-am
 plified/Mutated Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05751018
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635342-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07635342)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Pyro
 tinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Can
 cer\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07635342
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708194-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT07708194)
DESCRIPTION:Pyrotinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: En
 tinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive 
 Breast Cancer After Trastuzumab Failure\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 08194
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208410-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:Pyrotinib\, phase 1/2.\nStudy: A Clinical Study of JS105 in Com
 bination With Other Anti-tumor Therapies in Patients With Solid Tumors\nEs
 timated primary completion: 26 February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973525-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06973525)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: This
  Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cance
 r by Implementing a Dynamic Monitoring-guided Treatment Strategy.\nEstimat
 ed primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06973525
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03980054-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT03980054)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: A Study of Evaluating The Effects 
 Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast C
 ancer\nEstimated primary completion: June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03980054
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975475-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06975475)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: SHR-A1811 and THPy in First or Sec
 ond Line for HER2 Positive Advanced Breast Cancer Brain Metastases\nEstima
 ted primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06975475
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973319-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT04973319)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Trastuzumab Combined With Pertuzum
 ab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy\nEsti
 mated primary completion: 1 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04973319
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04983121-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT04983121)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Efficacy and Safety of Pyrotinib M
 aleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patient
 s\nEstimated primary completion: 15 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04983121
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393425-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07393425)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Neoadjuvant Trastuzumab Deruxtecan
  (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer\nEstimated primary comple
 tion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07393425
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Pyrotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoad
 juvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harbo
 ring Rare Mutations.\nEstimated primary completion: 1 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528716-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT07528716)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Artificial Intelligence Model-Guid
 ed Neoadjuvant Anti-HER2 Targeted Therapy\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7528716
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745740-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT05745740)
DESCRIPTION:Pyrotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced o
 r Metastasis NSCLC With HER2 Mutation\nEstimated primary completion: 1 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT057
 45740
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06718335-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pyrotinib: Phase na readout est. (NCT06718335)
DESCRIPTION:Pyrotinib\, phase na\, HER2-Positive Breast Cancer.\nStudy: Pyr
 otinib in HER2-positive Early Breast Cancer\nEstimated primary completion:
  30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/py
 rotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06718335
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Study of Precision Treatment for R
 are Tumours in China Guided by PDO and NGS\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyr
 otinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06692491
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014410-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07014410)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Pyrotinib Combined With Dalpicicli
 b Combined With Letrozole in ER-positive and HER2-positive Advanced Breast
  Cancer\nEstimated primary completion: 31 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07014410
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Fuda
 n University Shanghai Cancer Center Breast Cancer Precision Platform Serie
 s Study- Neoadjuvant Therapy\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pyrotinib: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Pyrotinib\, phase 2/3.\nStudy: Precision Medicine for Immunothe
 rapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyro
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07653451
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832904-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06832904)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Neoa
 djuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Brea
 st Cancer (NEOTORCH-BREAST05)\nEstimated primary completion: January 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06832904
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05328440-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT05328440)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Treatment of Dalpiciclib Combined 
 With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-
 Her-02)\nEstimated primary completion: 1 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05328440
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05841381-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280506
DTEND;VALUE=DATE:20280507
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT05841381)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Adjuvant Study of Pyrotinib in Com
 bination With Trastuzumab in HER2 Positive Invasive Breast Cancer\nEstimat
 ed primary completion: 6 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05841381
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797218-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT07797218)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Neoadjuvant Pyrotinib-to-pertuzuma
 b in HER2+ eBC\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07797218
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Precision Treatment of Recurrent/M
 etastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstimated p
 rimary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019337-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07019337)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Oral
  Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-posit
 ive Metastatic Breast Cancer\nEstimated primary completion: 31 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07019337
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132242-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07132242)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: SHR-
 A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive
  Breast Cancer\nEstimated primary completion: 30 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07132242
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180082-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07180082)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Continuous or Intermittent Pyrotin
 ib for HER2-positive Advanced Breast Cancer\nEstimated primary completion:
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyro
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07180082
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836257-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07836257)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: A Phase II Study of Trastuzumab De
 ruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer Af
 ter Progression on T-DXd\nEstimated primary completion: 30 October 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07836257
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610720-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07610720)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Dalpiciclib\, Anti-HER2 Therapy\, 
 and Endocrine Therapy for Hormone-Receptor-Positive\, HER2-Positive Metast
 atic Breast Cancer\nEstimated primary completion: 1 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07610720
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04646759-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT04646759)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Fulvestrant or Capecitabine Combin
 ed With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer\nEstimated primary
  completion: 14 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04646759
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05769010-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT05769010)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Study of SHR-A1811 in HER2-express
 ion Advanced Breast Cancer With Brain Metastases\nEstimated primary comple
 tion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05769010
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07615751-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT07615751)
DESCRIPTION:Pyrotinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Pyro
 tinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docet
 axel in Advanced HER2-Positive Breast Cancer\nEstimated primary completion
 : 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 yrotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07615751
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05575804-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT05575804)
DESCRIPTION:Pyrotinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: GQ
 1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic B
 reast Cancer\nEstimated primary completion: 31 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05575804
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340398-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07340398)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: Neoadjuvant Trastuzumab-rezetecan 
 Plus Pertuzumab or Nab-Paclitaxel\, Carboplatin\, Trastuzumab\, and Pyroti
 nib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Co
 mbined With Chemotherapy in HER2-Positive Early Breast Cancer\nEstimated p
 rimary completion: 31 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07340398
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417241-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07417241)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: SHR-
 A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Br
 east Cancer: A Randomized Study\nEstimated primary completion: 31 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07417241
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910398-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT05910398)
DESCRIPTION:Pyrotinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Cont
 inuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-p
 ositive Breast Cancer\nEstimated primary completion: April 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05910398
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179939-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07179939)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Main
 tenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metasta
 tic Breast Cancer: A Phase II Study\nEstimated primary completion: 30 Dece
 mber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0717
 9939
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053150-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07053150)
DESCRIPTION:Pyrotinib\, phase 2.\nStudy: A Prospective\, Open-label\, Explo
 ratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Comb
 ined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive Sy
 stem Tumors\nEstimated primary completion: 31 December 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07053150
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892274-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT07892274)
DESCRIPTION:Pyrotinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: Tras
 tuzumab Rezetecan Followed by Pyrotinib\, Fulvestrant\, and Dalpiciclib in
  HR-Positive\, HER2-Positive Advanced Breast Cancer\nEstimated primary com
 pletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07892274
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06278870-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT06278870)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: Disitamab Vedotin + Pyrotinib Vers
 us THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinic
 al Trial\nEstimated primary completion: 30 June 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06278870
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600164-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Pyrotinib: Phase 4 readout est. (NCT07600164)
DESCRIPTION:Pyrotinib\, phase 4\, HER2-Positive Breast Cancer.\nStudy: Real
 -world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Br
 east Cancer\nEstimated primary completion: 30 December 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07600164
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766772-2207@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT07766772)
DESCRIPTION:Pyrotinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tras
 tuzumab Rezetecan Followed by Pyrotinib\, and Trastuzumab Combined With Ca
 pecitabine as First-line Treatment for Advanced HER2-positive Breast Cance
 r\nEstimated primary completion: 31 December 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07766772
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
